Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL575048 | 0.86 | SMN1; SMN2 (0.41) | SMN1; SMN2GAANPC1HTTCNR2 | |
| SCHEMBL934512 | 0.79 | ALDH1A1 (0.43) | SMN1; SMN2ALDH1A1KDM4EGAALMNA | |
| SCHEMBL10797533 | 0.69 | ALDH1A1 (0.38) | SMN1; SMN2ALDH1A1NPC1HTTCNR2 | |
| SCHEMBL15580643 | 0.68 | SMN1; SMN2 (0.38) | SMN1; SMN2GAACNR2LMNARAB9A | |
| SCHEMBL1711015 | 0.67 | MAPT (0.53) | SMN1; SMN2ALDH1A1KDM4EGAALMNA | |
| SCHEMBL10794120 | 0.66 | CNR2 (0.39) | SMN1; SMN2ALDH1A1CNR2RAB9AMAPT | |
| SCHEMBL21524080 | 0.66 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1KDM4EGAALMNA | |
| SCHEMBL10793017 | 0.65 | MCHR1 (0.44) | ALDH1A1NPC1HTTCNR2L3MBTL1 | |
| SCHEMBL6788044 | 0.65 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1KDM4EGAANPC1 | |
| SCHEMBL10798211 | 0.65 | ALDH1A1 (0.41) | ALDH1A1CNR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9983218-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180024144-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-9625475-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20150353550-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2015-12-10 | — | — | US | disclosed |
| US-9063126-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2015-06-23 | — | — | US | disclosed |
| EP-2344505-A2 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20100249105-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100087471-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2010036998-A2 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249105-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | SMN1; SMN2 3913/4885ALDH1A1 1307/4885KDM4E 1720/4885 |
| US-20180024144-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | SMN1; SMN2 3913/4885ALDH1A1 1307/4885KDM4E 1720/4885 |
| US-20100087471-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | SMN1; SMN2 3913/4885ALDH1A1 1307/4885KDM4E 1720/4885 |
| US-20150353550-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | SMN1; SMN2 3913/4885ALDH1A1 1307/4885KDM4E 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.